NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

Search

Lonza Group AG

Затворен

СекторЗдравеопазване

571.6 0.99

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

566

Максимум

573.6

Ключови измерители

By Trading Economics

Приходи

-22M

307M

Продажби

460M

3.5B

P/E

Средно за сектора

64.697

56.602

EPS

4.31

Дивидентна доходност

0.69

Марж на печалбата

8.729

Служители

17,995

EBITDA

-60M

764M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+13.04% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.69%

2.45%

Следващи печалби

23.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-561M

42B

Предишно отваряне

570.61

Предишно затваряне

571.6

Lonza Group AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.05.2025 г., 05:18 ч. UTC

Печалби

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18.02.2025 г., 12:22 ч. UTC

Придобивния, сливания и поглъщания

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12.12.2024 г., 09:26 ч. UTC

Придобивния, сливания и поглъщания

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12.12.2024 г., 07:45 ч. UTC

Придобивния, сливания и поглъщания

Lonza Streamlines Business With Capsules Unit Exit -- Update

12.12.2024 г., 06:52 ч. UTC

Придобивния, сливания и поглъщания

Lonza Streamlines Organizational Structure

9.05.2025 г., 14:45 ч. UTC

Пазарно говорене

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9.05.2025 г., 14:42 ч. UTC

Пазарно говорене

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8.04.2025 г., 07:34 ч. UTC

Пазарно говорене

Lonza Well Protected From Tariffs -- Market Talk

29.01.2025 г., 08:11 ч. UTC

Пазарно говорене
Печалби

Lonza's Outlook Looks Positive -- Market Talk

29.01.2025 г., 07:22 ч. UTC

Пазарно говорене
Печалби

Lonza Had a Mixed Year Across Divisions -- Market Talk

29.01.2025 г., 07:11 ч. UTC

Пазарно говорене
Печалби

Lonza's Results Don't Contain Any Surprises -- Market Talk

29.01.2025 г., 06:26 ч. UTC

Топ новини
Печалби

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16.01.2025 г., 10:32 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Lonza's Midterm Outlook Is Positive -- Market Talk

16.12.2024 г., 22:03 ч. UTC

Топ новини

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13.12.2024 г., 08:07 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12.12.2024 г., 08:51 ч. UTC

Пазарно говорене
Печалби
Придобивния, сливания и поглъщания

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12.12.2024 г., 08:02 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12.12.2024 г., 05:59 ч. UTC

Придобивния, сливания и поглъщания

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12.12.2024 г., 05:59 ч. UTC

Придобивния, сливания и поглъщания

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12.12.2024 г., 05:58 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12.12.2024 г., 05:58 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12.12.2024 г., 05:58 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12.12.2024 г., 05:57 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12.12.2024 г., 05:55 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12.12.2024 г., 05:54 ч. UTC

Придобивния, сливания и поглъщания

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12.12.2024 г., 05:54 ч. UTC

Придобивния, сливания и поглъщания

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12.12.2024 г., 05:53 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12.12.2024 г., 05:53 ч. UTC

Придобивния, сливания и поглъщания

Lonza Sees Flat 2024 CER Sales Growth

12.12.2024 г., 05:52 ч. UTC

Придобивния, сливания и поглъщания

Lonza Backs 2024 View

12.12.2024 г., 05:52 ч. UTC

Придобивния, сливания и поглъщания

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

Сравнение с други в отрасъла

Ценова промяна

Lonza Group AG Прогноза

Ценова цел

By TipRanks

13.04% нагоре

12-месечна прогноза

Среден 645 CHF  13.04%

Висок 670 CHF

Нисък 630 CHF

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Lonza Group AG през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

3

Купи

1

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.